All In Biotech

Drug Trial Radar · NCT05630612

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)

Effects of Simultaneous ETA & AT1 Receptor Antagonism on Endothelial Function & Vascular Stiffness in ANCA-associated Vasculitis (SPARsentan in VASCulitis - SPARVASC)

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

32

Actual

Start

Dec 8, 2022

Primary completion

Jul 18, 2024

Study completion Sep 1, 2027

Sponsor

Lead sponsor
University of EdinburghAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Travere Therapeutics, Inc.
First posted
Nov 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ANCA-associated vasculitis is an autoimmune disease that causes damage to blood vessels. This leads to organ damage with the number of organs affected and the severity of damage varying significantly between patients. Vasculitis patients also have a very high risk of heart attacks and strokes, called cardiovascular disease. A chemical called 'endothelin', produced by the blood vessels, causes vessels to stiffen and raises blood pressure and this associates with cardiovascular risk. The investigators have previously shown that by blocking the effects of endothelin you reduce vessel stiffness, lower blood pressure and improve vessel function. However, these studies only blocked endothelin for a few hours. Now, the investigators would like to see if it is possible to maintain these benefits by blocking endothelin for longer. Sparsentan is a tablet that blocks endothelin and lowers blood pressure. The investigators plan to give sparsentan to patients with vasculitis for 6 weeks. To determine if any beneficial effects of sparsentan are due to blood pressure lowering the investigators will give another group of vasculitis patients a tablet called irbesartan which lowers blood pressure but does not block endothelin. The investigators will compare the results between the two groups.

Conditions

  • ANCA Associated Vasculitis
  • Cardiovascular Diseases
  • Kidney Diseases

Interventions

  • SparsentanDrug

    6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Forearm blood flowTime frame: Comparing baseline to after 6 weeks of intervention.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Cardiovascular Science, Queen's Medical Research Institute, 47 Little France Crescent

    Edinburgh, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.